Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptom
Conditions
Keywords
Microsphere, Transcatheter Arterial chemo-embolization
Brief summary
In this proposal, the investigators plan to conduct a clinical trial to validate the efficacy and safety of microspheres (T-ACE Beads).
Detailed description
T-ACE Beads can be used for prostatic arterial embolization safely and efficiently. Furthermore, investigator's microspheres has advantageous characteristics in biodegradability, drug delivery capability, and cost-effectiveness. After the clinical trial, we anticipate introducing a new microsphere for Lower Urinary Tract Symptom/Benign prostatic hyperplasia patients, which is beneficial to the participants in precise medicine as well as in the pharmaceutical and medical device industry.
Interventions
DEVICETaiwan ACE Beads
Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
Sponsors
The Industrial Technology Research Institute
National Cheng Kung University
National Research Program for Biopharmaceuticals, Taiwan
National Cheng-Kung University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
A. Men ≥ 50 years of age. Healthy patients or volunteers without diagnosis of Lower urinary tract symptoms (LUTS) / Benign prostatic hyperplasia (BPH) will not be included. B. Patients diagnosed of LUTS / BPH，International Prostate Symptom Score \> 12 with mild to severe symptom of LUTS. C. Prostate volume \> 50 mL. D. Urinary flow rate \<15 mL / sec. E. Ineffectiveness after 6 months of previous medical treatment, or the side effects are too difficult to tolerate.
Exclusion criteria
If patients meet any of the following criteria they may not be entered into the study: A. Major pelvic disease, or other malignancies. B. Prostate specific antigen of serum \> 10 ng/mL, malignant tumor not yet rule out (prostate specific antigen PSA\>10 ng/mL). C. Had Prostate surgery. D. Chronic bacterial prostatitis. E. Renal dysfunction or bladder diverticulum stones caused by prostate disease obstruction. F. Main organs (heart, lung, liver, kidney) dysfunction who are not eligible for clinical trials under physicians' consideration. G. White Blood Cell\< 2000 or Severe thrombocytopenia（Platelet count \<50,000/μL)，or blood coagulation abnormalities uncorrectable . H. Unable to follow-up by MRI 3 times. I. Unable to follow-up by ultrasound or CT scan. J. Unwilling to sign a written informed consent form. K. Allergic to Iodine or other injections. L. Acute bacterial prostatitis. M. Patients with active urinary tract infections or recurrent urinary tract infections (\>2/years), prostatitis, or interstitial cystitis. N. Cases of biopsy proven prostate, bladder, or urethral cancer. O. Patients with glomerular filtration rates less than 40 who are not already on dialysis. P. Patients with bilateral internal iliac arterial occlusion. Q. Patients with causes of bladder obstruction not due to BPH (eg urethral stricture, bladder neck contraction, etc). R. Patients with neurogenic or bladder atonia. S. Patients where embolization is not possible distal to collateral vessels feeding non-prostatic tissue. T. Patients with major neurologic illnesses which could have symptoms that may be similar to or confused for BPH (eg multiple sclerosis, Shy-Drager syndrome, spinal cord injury, etc.). U. Patients with urethral stents. V. Other than hemorrhoidectomy or pelvic irradiation, patients who have undergone prior rectal surgery. W. Patients who have started or changed their dosage of alpha blockers or 5-alpha reductase inhibitors in the month prior to prostatic artery embolization. X. Allergic to pharmaceutical excipients related to Microspheres.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Patients Survival (Safety) | An average of 12 weeks. | Survival rate was evaluated since treatment day until the date of death or final observation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change on Patient's Symptoms | Before treatment, one and three months after treatment | Change on patients' International Prostate Symptom Score (IPSS) |
| Change on Prostate Volume | Before treatment, one and three months after treatment. | Prostate volume measured using MRI |
| Change in serum Prostate Specific Antigen (PSA) concentration | Before treatment, one and three months after treatment. | Measurement of Prostate Specific Antigen in patients undergoing this treatment. |
Countries
Taiwan
Contacts
Primary ContactXi-Zhang Lin, MD
Backup ContactHui-Yu Hung, Bachelor
Outcome results
None listed